Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Moschini

Showing results (551-560 of 561) with videos related to

Pageof 57
Sort By:
BMC Cancer|April 30, 2025
Development and validation of a prediction model for early recurrence in upper tract urothelial carcinoma treated with radical nephroureterectomyYi-Ju Chou, Hao-Lun Luo, Hung-Jen Wang, et al.
BJU International|October 6, 2025
Temporal trends and clinical determinants of urinary diversion after radical cystectomyFrancesco Pellegrino, Mario de Angelis, Pietro Scilipoti, et al.
World Journal of Urology|October 28, 2025
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year studyMario de Angelis, Francesco Pellegrino, Pietro Scilipoti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 16, 2026
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerPietro Scilipoti, Mario de Angelis, Constance Thibault, et al.
Urologic Oncology|July 19, 2022
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancerWojciech Krajewski, Júlia Aumatell, José Daniel Subiela, et al.
Nature Reviews. Urology|April 1, 2026
Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensusRoberto Contieri, Paolo Gontero, Rodolfo Hurle, et al.
World Journal of Urology|June 10, 2026
Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomesValerio Santarelli, Vincenzo Asero, Roberta Corvino, et al.
BJU International|August 29, 2025
Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapyJosé Daniel Subiela, Irene de la Parra, Javier Taborda, et al.
European Urology Oncology|May 21, 2025
Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder CancerRoberto Contieri, Alberto Martini, Irene J Beijert, et al.
European Urology|May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 57

Showing results (551-560 of 561) with videos related to

Sort By:
Pageof 57
BMC Cancer|April 30, 2025
Development and validation of a prediction model for early recurrence in upper tract urothelial carcinoma treated with radical nephroureterectomyYi-Ju Chou, Hao-Lun Luo, Hung-Jen Wang, et al.
BJU International|October 6, 2025
Temporal trends and clinical determinants of urinary diversion after radical cystectomyFrancesco Pellegrino, Mario de Angelis, Pietro Scilipoti, et al.
World Journal of Urology|October 28, 2025
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year studyMario de Angelis, Francesco Pellegrino, Pietro Scilipoti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 16, 2026
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerPietro Scilipoti, Mario de Angelis, Constance Thibault, et al.
Urologic Oncology|July 19, 2022
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancerWojciech Krajewski, Júlia Aumatell, José Daniel Subiela, et al.
Nature Reviews. Urology|April 1, 2026
Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensusRoberto Contieri, Paolo Gontero, Rodolfo Hurle, et al.
World Journal of Urology|June 10, 2026
Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomesValerio Santarelli, Vincenzo Asero, Roberta Corvino, et al.
BJU International|August 29, 2025
Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapyJosé Daniel Subiela, Irene de la Parra, Javier Taborda, et al.
European Urology Oncology|May 21, 2025
Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder CancerRoberto Contieri, Alberto Martini, Irene J Beijert, et al.
European Urology|May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 57